Regulation of hormonal therapy resistance by cell cycle machinery

Gene Therapy and Molecular Biology

Volumn 12, Issue 2, 2008, Pages 395-404

  Nair, Binoj Chandrasekharan ^a   Vadlamudi, Ratna K ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Antiestrogens; Breast cancer; CDKs; Cell cycle; Co regulators; Estrogen; Estrogen receptor; Therapy resistance

Indexed keywords

EID: 77649145385     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH (2008) Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A 105, 288-293.
2. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, antiestrogens in breast cancer. Cancer Res 64, 3198-3208.
3. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A (1996) 17"-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12, 2315-2324.
4. Ariazi EA, Ariazi JL, Cordera F, Jordan VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6, 195-216.
5. Balasenthil S and Vadlamudi RK (2003) Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 278, 22119-22127.
6. Barnes CJ, Vadlamudi RK, Kumar R (2004) Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 61, 281-291.
7. Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9, 2811-2818.
8. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005-1011.
9. Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R (2002) Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptorpositive breast cancer cells. Oncogene 21, 8158-8165.
10. Bocchinfuso WP and Korach KS (1997) Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 2, 323-334.
11. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 117, 218-228.
12. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 97, 9042-9046.
13. Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ, Musgrove EA, Sutherland RL (2003) p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 63, 4322-4326.
14. Chandrasekharan Nair B, Nair S, Chakravarty D, Rajhans R, Cortez V, Tekmal R, Vadlamudi R. (2008a) PELP1/MNAR: A novel CDKs substrate and regulator of pRb/E2F pathway. In: Proceedings of the Annual Meeting of the American Association for Cancer Research (Abstract no: 4222)
15. Chandrasekharan Nair B, Nair S, Chakravarty D, Yew R, Tekmal R, Vadlamudi R. (2008b) Modulation of hormone therapy resistance by CDK2-PELP1 axis. CTRC-SABCS conference (abstract no: 3022)
16. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR (1999) Regulation of transcription by a protein methyltransferase. Science 284, 2174-2177.
17. Chu I, Blackwell K, Chen S, Slingerland J (2005) The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65, 18-25.
18. Coverley D, Marr J, Ainscough J (2005) Ciz1 promotes mammalian DNA replication. J Cell Sci 118, 101-112.
19. den HP, Rayala SK, Coverley D, Kumar R (2006) Ciz1, a Novel DNA-binding coactivator of the estrogen receptor α, confers hypersensitivity to estrogen action. Cancer Res 66, 11021-11029.
20. Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza MA, Azambuja E, Paesmans M, Larsimont D, Buyse M, Harris A, Piccart M, Martiat P, Sotiriou C (2006) Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer 119, 2539-2545.
21. Dhillon NK and Mudryj M (2002) Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21, 4626-4634.
22. Donovan JC, Milic A, Slingerland JM (2001) Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276, 40888-40895.
23. Dubik D, Dembinski TC, Shiu RP (1987) Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47, 6517-6521.
24. El MS, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D, Theillet C, Vandel L, Bedford MT, Sardet C (2006) Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A 103, 13351-13356.
25. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J (2001) Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 21, 794-810.
26. Frietze S, Lupien M, Silver PA, Brown M (2008) CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res 68, 301-306.
27. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54, 1812-1817.
28. Green KA and Carroll JS (2007) Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 7, 713-722.
29. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87, 905-931.
30. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL (2003) Tamoxifen functions as a molecular agonist inducing cell cycleassociated genes in breast cancer cells. Mol Cancer Res 1, 300-311.
31. Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A (1997) Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett 113, 123-130.
32. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL (2002) Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 62, 6916-6923.
33. Ichikawa A, Ando J, Suda K (2008) G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. Hum Cell 21, 28-37.
34. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91-104.
35. Ishii Y, Waxman S, Germain D (2008) Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res 68, 852-860.
36. Jepsen K and Rosenfeld MG (2002) Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci 115, 689-698.
37. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G (2005) Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65, 8009-8016.
38. Kasten M and Giordano A (2001) Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 20, 1832-1838.
39. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF (1999) Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5, 2069-2076.
40. Khan MM, Hadman M, Wakade C, De Sevilla LM, Dhandapani KM, Mahesh VB, Vadlamudi RK and Brann DW (2005) Cloning, expression, localization of MNAR/PELP1 in rodent brain: colocalization in estrogen receptor-α- but not in gonadotropin-releasing hormone-positive neurons. Endocrinology 146, 5215-27
41. Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD (2004) Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol 92, 63-71.
42. Kilker RL and Planas-Silva MD (2006) Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Cancer Res 66, 11478-11484.
43. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P (1987) Functional domains of the human estrogen receptor. Cell 51, 941-951.
44. Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME (2000) Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20, 8667-8675.
45. Leary A and Dowsett M (2006) Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br J Cancer 95, 661-6
46. Lewis-Wambi JS and Jordan VC (2005) Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs) Breast Dis 24, 93-105
47. Louie MC, Revenko AS, Zou JX, Yao J, Chen HW (2006) Direct control of cell cycle gene expression by proto-oncogene product ACTR, its autoregulation underlies its transforming activity. Mol Cell Biol 26, 3810-3823.
48. Louie MC, Zou JX, Rabinovich A, Chen HW (2004) ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24, 5157-5171.
49. Lu F, Gladden AB, Diehl JA (2003) An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63, 7056-7061.
50. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 90, 11162-11166.
51. McDonnell DP and Norris JD (2002) Connections and regulation of the human estrogen receptor. Science 296, 1642-1644.
52. McGuire WL and Clark GM (1992) Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326, 1756-1761.
53. McKenna NJ, Lanz RB, O'Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20, 321-344.
54. Michalides R, van TH, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van DP (2002) Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 86, 402-408.
55. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283, 29897-29903.
56. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A (1991) A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512-515.
57. Mukherjee S and Conrad SE (2005) c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280,17617-25.
58. Mussi P, Yu C, O'Malley BW, Xu J (2006) Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol 20, 3105-3119.
59. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17, 5338-5347.
60. Pacilio C, Germano D, Addeo R, Altucci L, Petrizzi VB, Cancemi M, Cicatiello L, Salzano S, Lallemand F, Michalides RJ, Bresciani F, Weisz A (1998) Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res 58, 871-876.
61. Pedram A, Razandi M, Aitkenhead M, Hughes CC and Levin ER (2002) Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 27,50768-75
62. Perez-Tenorio G, Berglund F, Esguerra MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2006) Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. Int J Oncol 28, 1031-1042.
63. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA (2001) AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res 61, 3858-3862.
64. Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M (2003) High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 21, 3594-3600.
65. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K (2001) Tumor-specific proteolytic processing of cyclin E generates hyperactive lowermolecular-weight forms. Mol Cell Biol 21, 6254-6269.
66. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL (1998a) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18, 4499-4508.
67. Prall OW, Rogan EM, Sutherland RL (1998b) Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol 65, 169-174.
68. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272, 10882-10894.
69. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH (2007) Pathways to tamoxifen resistance. Cancer Lett 256, 1-24.
70. Rogatsky I, Trowbridge JM, Garabedian MJ (1999) Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 274, 22296-22302.
71. Ru LW, Chen CC, Liu S, Safe S (2006) 17"-estradiol (E2) induces cdc25A gene expression in breast cancer cells by genomic and non-genomic pathways. J Cell Biochem 99, 209-220.
72. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M (2008) Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 14, 1767-1774.
73. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96, 926-935.
74. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG (2003) Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22, 4898-4904.
75. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90, 1942-1948.
76. Swanton C and Downward J (2008) Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer Cell 13, 83-85.
77. Trowbridge JM, Rogatsky I, Garabedian MJ (1997) Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A 94, 10132-10137.
78. Tsai MJ and O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63, 451-486.
79. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R (2001) Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor α . J Biol Chem 276, 38272-38279.
80. Varma H and Conrad SE (2000) Reversal of an antiestrogenmediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain. Oncogene 19, 4746-4753.
81. Varma H, Skildum AJ, Conrad SE (2007) Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells. PLoS ONE 2, e1256.
82. Venditti M, Iwasiow B, Orr FW, Shiu RP (2002) C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 99, 35-42.
83. Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES (2008) Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 68, 5628-5638.
84. Warner M, Nilsson S, Gustafsson JA (1999) The estrogen receptor family. Curr Opin Obstet Gynecol 11, 249-254.
85. Wilcken NR, Prall OW, Musgrove EA, Sutherland RL (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3, 849-854.
86. Yadav N, Lee J, Kim J, Shen J, Hu MC, Aldaz CM, Bedford MT (2003) Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci U S A 100, 6464-6468.
87. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ (2008) MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283, 31079-31086.